CorMedix
CRMD
194 hedge funds and large institutions have $345M invested in CorMedix in 2026 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 68 increasing their positions, 59 reducing their positions, and 21 closing their positions.
54% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $8.06M
43% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 21
23% more capital invested
Capital invested by funds: $280M → $345M (+$65.6M)
15% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 59
4.02% more ownership
Funds ownership: 52.09% → 56.11% (+4%)
3% more funds holding
Funds holding: 188 → 194 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.95M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$3.43M |
| 3 |
BlackRock
New York
|
+$2.82M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.68M |
| 5 |
HF
HRT Financial
New York
|
+$2.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sculptor Capital
New York
|
-$2.28M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$2.28M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.01M |
| 4 |
Lazard Asset Management
New York
|
-$1.76M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.47M |
CRMD Hedge Fund Activity: Q2 2026 in Review
194 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q2 2026, worth a combined $345M — up 23% from $280M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CRMD positions and 21 closed out — a net gain of 9 holders — while 68 added to existing stakes and 59 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.95M. The largest seller was Sculptor Capital, exiting entirely with an estimated $2.28M sold.
- 194 institutional investors held CorMedix (CRMD) as of Q2 2026, up from 188 in Q1 2026.
- Funds reported $345M of CorMedix stock for Q2 2026, up 23% quarter-over-quarter.
- 30 funds opened new CorMedix positions in Q2 2026 and 21 closed out, a net change of +9 holders.
- The largest CorMedix buyer in Q2 2026 was Armistice Capital, an estimated $3.95M added.
- The largest CorMedix seller in Q2 2026 was Sculptor Capital, an estimated $2.28M sold.
Based on aggregated 13F filings for Q2 2026.